Regulators to probe Bayer’s Xarelto trial results
December 10, 2015Medical Communications, Research and Development
Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …
Novo Nordisk files for new insulin approval
December 10, 2015Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application
Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
‘Female Viagra’ CEO leaves company
December 10, 2015Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma
Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …
EMA sets out new five-year plan
December 9, 2015Research and Development EMA, Guido Rasi
The European Medicines Agency’s (EMA) new executive director, Professor Guido Rasi, outlined his vision for his five-year mandate at the …
Early UK access for AstraZeneca lung cancer drug
December 9, 2015AstraZeneca, Early Access to Medicines Scheme, Tagrissa, eams, lung cancer, non small cell lung cancer, non-small cell lung cancer, osimertinib
UK patients will be among the first in Europe to have free access to AstraZeneca’s cancer drug osimertinib, after the …
Janssen submits Stelara for EU approval for Crohn’s
December 9, 2015Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab
Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …
Two new corporate affairs leads appointed at Pfizer
December 9, 2015Medical Communications Pfizer, corporate affairs
Pfizer has appointed MacKay Jimeson and Niesha Foster as corporate affairs leads. The company recently restructured its global pharma business …
Daiichi Sankyo rocked by further job losses
December 9, 2015Manufacturing and Production Daiichi, Daiichi Sankyo
The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut …
New member appointed to Roche board of directors
December 9, 2015Business Services Roche
The Roche board of directors has proposed Dr Claudia Süssmuth Dyckerhoff, currently senior partner at McKinsey & Company, for election …
Former Quintiles director joins IDEA Pharma as MD
December 9, 2015Medical Communications, Sales and Marketing IDEA Pharma, Mark Forbes Irving
IDEA Pharma has appointed Mark Forbes Irving as managing director. With over 20 years’ industry experience, the new managing director joins …
Researchers launch CAR-T cell therapy trial in head and neck cancer
December 9, 2015Research and Development CAR-T, CAR-T therapy, Cancer, head and neck cancers, oncology R&D
A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …
Novartis reaches 300 million free antimalarial treatments
December 9, 2015Manufacturing and Production, Research and Development Coartem, Novartis, antimalarial treatment, malaria, non-profit
Novartis has reached a delivery milestone of 300 million paediatric antimalarial treatments, having supplied its Coartem dispersible without profit to …
The age of collaboration: why pharma companies now have to work together
December 9, 2015Research and Development R&D, co-operation, collaboration, pharma
It seems 2015 may be remembered as the year of the mega merger; the year when all records were broken …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
Gilead awaits EU decision on hep C combo treatment
December 8, 2015Research and Development EMA, Gilead, SOF/VEL, accelerated assessment, hepatitis C, sovaldi, velpatasvir
The EMA has granted Gilead Sciences an accelerated assessment for its application for a new Sovaldi combination treatment.The combination contains …
ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
Strong cancer trial data for Janssen at ASH 2015
December 8, 2015Research and Development Cancer, Janssen, darzalex, imbruvica, oncology
Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
Sandoz announces biosimilar successes
December 8, 2015Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim
Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …
Lilly pulls plug on basal insulin Peglispro
December 8, 2015Manufacturing and Production R&D, basal insulin peglispro, diabetes, lilly, peglispro, phase III failure
Lilly has decided to pull out of filing its diabetes drug basal insulin peglispro, after failing to convince regulators and …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
